Analysts’ Recommendations for AstraZeneca and Peers

Investors have a lot to watch for when it comes to AstraZeneca (AZN) stock, with key events expected in the company’s research pipeline and higher uptake expected for the company’s new medicines on the market. In this series, we’ll explore what analysts think of AstraZeneca’s stock potential, financial performance, valuation, and more. Of the six analysts covering AstraZeneca, four have recommended “buy” or a higher rating, while two have recommended “hold.” Their mean rating for the stock is 1.8, and their target price is $39.09.